OncoSenX
Hank received his Ph.D. in Cancer Genetics and Cellular and Molecular Biology from the Roswell Park Cancer Institute in 2014 with a research focus on drug development and tumor initiation. Hank then took a position as a Post-Doc in the Department of Anatomy at the University of California San Francisco, expanding his research expertise to include neurobiology and aging therapies. Hank now supports OncoSenX’s R&D efforts.
This person is not in any offices
OncoSenX
OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid tumors based on transcriptional activity using a unique lipid nanoparticle and plasmid DNA.